elmono,
You look at things from the position of a trader, I myself, like a lot of holders on this board, am a 'long'.
And if someone looks at INSM through 'long' glasses the possibilies are endless:
I've had a long hard look at the possible treatments which are in the works for MMD and as far as I was able to ascertain, there's only one serious candidate until gene therapy hits the market and that's iPlex.
What's more: there are already Italians treated with iPlex for MMD, of which one is known to have gained 5 kg of muscular mass during treatment with iPlex. Which is extremely successful.
Remember also: the current Phase II MMD trial by Richard Moxley is about safety and efficacy, so if that test is successful, I would be highly surprised if a fast track for iPlex for the MMD indication didn't belong to the possibilities.
And that's only MMD we're talking about.
Concerning Europe:
The patent system and the patents awarded are different in Europe than in the US, while the overall markets are about the same size. There's NO '414 patent equivalent in the EU. Nor will there ever be one due to prior art.
There has been a patent trial in Great Britain, but that only concerned short stature related indications ('515 patent equivalent) and was not continued by TRCA/DNA. Therefore the patent threat is much less for INSMED in the EU than in the US.
So I definitely expect to see a partner in the EU somewhere next year.
Also look at Asia: INSM is presenting the coming November 11th at Kobe, Japan their new room stable form of iPlex. Why there and not in the US? Think about it...
The coming month will be tough on longs, however: I'm personally convinced that we can start looking up after that.
E.
